lapatinib has been researched along with rtki cpd in 4 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (rtki cpd) | Trials (rtki cpd) | Recent Studies (post-2010) (rtki cpd) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 41 | 0 | 21 |
| 1,919 | 305 | 1,442 | 744 | 0 | 257 |
| Protein | Taxonomy | lapatinib (IC50) | rtki cpd (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.125 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1152 | |
| Fructose-1,6-bisphosphatase 1 | Homo sapiens (human) | 1.3 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 2.7 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.56 | |
| Tyrosine-protein kinase ABL2 | Homo sapiens (human) | 0.125 | |
| Epidermal growth factor receptor | Mus musculus (house mouse) | 0.1 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.56 | |
| MAP kinase-interacting serine/threonine-protein kinase 1 | Homo sapiens (human) | 0.53 | |
| Histamine H3 receptor | Rattus norvegicus (Norway rat) | 1.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Mazaideh, GM; Erdmann, F; Göllner, C; Rohe, A; Schmidt, M; Sippl, W; Wichapong, K | 1 |
| Brattain, MG; Conway, AN; Hauser, J; Hu, YP; Humphrey, L; Li, S; Vinci, MA; Wang, J; Willson, JK; Zborowska, E; Zhou, Y | 1 |
| Bissell, MJ; Furuta, S; Kenny, PA; Lee, SY; Lenburg, ME; Meier, R; Xu, R | 1 |
| Bodiga, S; Bodiga, VL; Thokala, S; Vemuri, PK | 1 |
4 other study(ies) available for lapatinib and rtki cpd
| Article | Year |
|---|---|
Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
Topics: Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Glycolipids; Humans; Membrane Proteins; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship | 2013 |
Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Topics: Animals; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; ErbB Receptors; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Tyrphostins; Xenograft Model Antitumor Assays | 2006 |
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-raf; Quinazolines; RNA Interference; Signal Transduction; Tyrphostins; Xenograft Model Antitumor Assays | 2012 |
Zinc pyrithione inhibits caspase-3 activity, promotes ErbB1-ErbB2 heterodimerization and suppresses ErbB2 downregulation in cardiomyocytes subjected to ischemia/reperfusion.
Topics: Amino Acid Chloromethyl Ketones; Animals; Benzothiazoles; Cardiotonic Agents; Caspase 3; Caspase Inhibitors; Cell Hypoxia; Chlorides; Down-Regulation; ErbB Receptors; Lapatinib; Leupeptins; Myocytes, Cardiac; Organometallic Compounds; Phosphorylation; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Multimerization; Pyridines; Quinazolines; Rats; Receptor, ErbB-2; RNA, Messenger; Thiones; Tyrphostins; Zinc Compounds | 2015 |